{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:56:03Z","timestamp":1778241363171,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2023R1A2C1006509"],"award-info":[{"award-number":["2023R1A2C1006509"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-024-03935-2","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:40:38Z","timestamp":1739493638000},"page":"398-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma with Localized Portal Vein Tumor Thrombosis (RESOLVE): Protocol for an Open-label, Multi-center, Single-arm Trial"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-8002","authenticated-orcid":false,"given":"Jin Woo","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyoung Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongho","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myoung-jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"3935_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"3935_CR2","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/hep.31187","volume":"72","author":"A Vitale","year":"2020","unstructured":"Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020;72:2206\u201318.","journal-title":"Hepatology"},{"key":"3935_CR3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s00330-016-4511-3","volume":"27","author":"JW Choi","year":"2017","unstructured":"Choi JW, Kim HC, Lee JH, et al. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol. 2017;27:1448\u201358.","journal-title":"Eur Radiol"},{"key":"3935_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/bjr\/tqae052","author":"H Hwang","year":"2024","unstructured":"Hwang H, Kim JH, Ko E, et al. Chemoembolization as First-Line treatment for hepatocellular carcinoma invading segmental portal vein with tumor burden limited to a monosegmental level. Br J Radiol. 2024. https:\/\/doi.org\/10.1093\/bjr\/tqae052.","journal-title":"Br J Radiol"},{"issue":"1155\u201363","key":"3935_CR5","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(1155\u201363): e2.","journal-title":"Gastroenterology"},{"key":"3935_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","volume":"68","author":"C Spreafico","year":"2018","unstructured":"Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68:724\u201332.","journal-title":"J Hepatol"},{"key":"3935_CR7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","volume":"59","author":"N Abouchaleh","year":"2018","unstructured":"Abouchaleh N, Gabr A, Ali R, et al. (90)Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med. 2018;59:1042\u20138.","journal-title":"J Nucl Med"},{"key":"3935_CR8","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u201336.","journal-title":"Lancet Oncol"},{"key":"3935_CR9","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913\u201321.","journal-title":"J Clin Oncol"},{"key":"3935_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3935_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"AL Hermann","year":"2020","unstructured":"Hermann AL, Dieudonne A, Ronot M, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296:673\u201384.","journal-title":"Radiology"},{"key":"3935_CR12","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342\u201352.","journal-title":"Hepatology"},{"key":"3935_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7:843\u201350.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3935_CR14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816\u201330.","journal-title":"Radiology"},{"key":"3935_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jvir.2019.10.020","volume":"31","author":"JW Choi","year":"2020","unstructured":"Choi JW, Lee JM, Kim HC, et al. Iatrogenic arterioportal fistula caused by radiofrequency ablation of hepatocellular carcinoma: clinical course and treatment outcomes. J Vasc Interv Radiol. 2020;31:728\u201336.","journal-title":"J Vasc Interv Radiol"},{"key":"3935_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jvir.2023.10.011","volume":"35","author":"JW Choi","year":"2024","unstructured":"Choi JW, Suh M, Paeng JC, Kim JH, Kim HC. Radiation major hepatectomy using ablative dose Yttrium-90 radioembolization in patients with hepatocellular carcinoma 5 cm or larger. J Vasc Interv Radiol. 2024;35:203\u201312.","journal-title":"J Vasc Interv Radiol"},{"key":"3935_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50:328\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3935_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"3935_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 Trial. J Nucl Med. 2024;65:264\u20139.","journal-title":"J Nucl Med"},{"key":"3935_CR20","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"3935_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","volume":"4","author":"SM Yoon","year":"2018","unstructured":"Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4:661\u20139.","journal-title":"JAMA Oncol"},{"key":"3935_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953\u201360.","journal-title":"JAMA Oncol"},{"key":"3935_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.14701\/ahbps.24-048","volume":"28","author":"TS Kim","year":"2024","unstructured":"Kim TS, Yang K, Choi GH, et al. Surgical outcome and risk scoring to predict survival after hepatic resection for hepatocellular carcinoma with portal vein tumor thrombosis. Ann Hepatobiliary Pancreat Surg. 2024;28:134\u201343.","journal-title":"Ann Hepatobiliary Pancreat Surg"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03935-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03935-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03935-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T14:53:58Z","timestamp":1741359238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03935-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3935"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03935-2","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jin Woo Choi has received research grants from Guerbet and NextBiomedical, speaker honoraria from Boston Scientific, SIRTEX, Guerbet, and Terumo, and a consultant fee from Samsung Healthcare. Gyoung Min Kim has received a speaker honorarium from Boston Scientific. Dongho Hyun has nothing to disclose. Myoung-jin Jang has nothing to disclose. Hyo-Cheol Kim has received speaker honoraria from SIRTEX and Guerbet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study will be in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent will be obtained from all individual participants who will be included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}